Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Nicole Neidhart

Nurse Practitioner, Women's Health Jacksonville, FL Nurse Practitioner

NPI 1750490819 CMS profile 10987259

915 W Monroe St Ste 100, Jacksonville, FL 32204

Open in the dashboard

General payments

$22,925

72 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Nicole Neidhart of Jacksonville, FL is reported in the CMS Open Payments database as having received $22,925 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Women's Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $27 2
2023 General $15,078 6
2022 General $6,955 25
2021 General $865 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Neidhart
  • Nurse Practitioner, Women's Health median
  • Middle half of Nurse Practitioner, Women's Health
  • National median

In program year 2025, general payments to Nicole Neidhart were reported at $0. Among 3,829 Nurse Practitioner, Women's Health profiles paid that year, the median was $124 and the middle half received between $42 and $307.

Show as a table
Year Nicole Neidhart Nurse Practitioner, Women's Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $865 $110 $33–$291 $132
2022 $6,955 $122 $40–$314 $149
2023 $15,078 $131 $40–$333 $160
2024 $27 $123 $43–$298 $164
2025 $0 $124 $42–$307 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AngioDynamics, Inc. $21,417 2 payments
  2. Janssen Pharmaceuticals, Inc $373 15 payments
  3. Bard Peripheral Vascular, Inc. $342 18 payments
  4. Medtronic, Inc. $281 12 payments
  5. Cardiovascular Systems Inc. $188 12 payments
  6. Philips Electronics North America Corporation $109 1 payment
  7. Siemens Medical Solutions USA, Inc. $43 2 payments
  8. Evofem Biosciences, Inc. $39 1 payment
  9. Abbott Laboratories $35 2 payments
  10. Boston Scientific Corporation $29 2 payments
  11. Other $69 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Long term medical supply or device loan $21,417 2 payments
  2. Food and Beverage $1,508 70 payments
Products named General payments · program years 2021–2024
  1. Auryon Laser System 100-120 Vac $21,417 2 payments
  2. XARELTO $390 16 payments
  3. Abre $211 8 payments
  4. Diamondback Peripheral $137 8 payments
  5. (9284) Stellarex $109 1 payment
  6. VENASEAL $45 3 payments
  7. COVERA $41 2 payments
  8. Phexxi $39 1 payment
  9. Artis zee multi-purpose $29 1 payment
  10. ESTROGEL $26 2 payments
  11. Other $193 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

120

Median for Certified Nurse Midwife: 28

Drug cost

$43,094

Median for Certified Nurse Midwife: $1,314

Branded share of claims

100%

Median for Certified Nurse Midwife: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 34 $42,240
Clopidogrel Clopidogrel Bisulfate Brand 86 $854

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,212 Part D prescribers listed as Certified Nurse Midwife; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$8,820

Medicare's payments for the services billed

Medicare patients

85

Average age 78

Services billed

98

44 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 52%
Diabetes 51%
Chronic kidney disease 39%
Depression 29%
Heart failure 28%
Cancer 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record